Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 20/20 | 0.98 |
| ▸ | ESRRB | O95718 | 8/20 | 0.82 |
| ▸ | ESR1 | P03372 | 6/20 | 0.82 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.80 |
| ▸ | ESRRA | P11474 | 2/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20841996 | 0.90 | ESRRG (1.00) | ESRRGESRRBESR1KCNH2ESRRA | |
| SCHEMBL20842034 | 0.90 | ESRRG (1.00) | ESRRGESRRBESR1KCNH2ESRRA | |
| SCHEMBL20842094 | 0.89 | ESRRG (1.00) | ESRRGESRRBESR1KCNH2ESRRA | |
| SCHEMBL20842030 | 0.88 | ESRRG (0.98) | ESRRGESRRBESR1KCNH2 | |
| SCHEMBL20842098 | 0.86 | ESRRG (1.00) | ESRRGESRRBESR1KCNH2ESRRA | |
| SCHEMBL20842003 | 0.86 | ESRRG (0.78) | ESRRGESRRBESR1KCNH2ESRRA | |
| SCHEMBL20842123 | 0.85 | ESRRG (0.98) | ESRRGESRRBESR1KCNH2ESRRA | |
| SCHEMBL24505351 | 0.85 | ESRRG (0.74) | ESRRGESRRBESR1KCNH2ESRRA | |
| SCHEMBL20842130 | 0.85 | ESRRG (0.75) | ESRRGESRRBESR1KCNH2ESRRA | |
| SCHEMBL21026533 | 0.85 | ESRRG (0.98) | ESRRGESRRBESR1KCNH2ESRRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109415313-B | Novel arylethene derivative and pharmaceutical composition containing the same as active ingredient | 诺麦塔制药有限公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-109563054-B | Novel arylethene derivative and pharmaceutical composition containing same as active ingredient | 大邱庆北尖端医疗产业振兴财团 | 2022-08-05 | — | — | CN | disclosed |
| EP-3480186-B1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | NOVMETAPHARMA CO LTD (KR) | 2022-06-15 | — | — | EP | disclosed |
| EP-3480186-B1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | NOVMETAPHARMA CO LTD (KR) | 2022-06-15 | — | — | EP | disclosed |
| EP-3459936-B1 | NOVEL ARYL ETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | DAEGU GYEONGBUK MEDICAL INNOVATION FOUND (KR) | 2022-04-27 | — | — | EP | disclosed |
| EP-3459936-B1 | NOVEL ARYL ETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | DAEGU GYEONGBUK MEDICAL INNOVATION FOUND (KR) | 2022-04-27 | — | — | EP | disclosed |
| US-11285226-B2 | Aryl ethene derivative and pharmaceutical composition containing same as active ingredient | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2022-03-29 | — | — | US | disclosed |
| US-10934303-B2 | Aryl ethene derivative and pharmaceutical composition containing same as active ingredient | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-03-02 | — | — | US | disclosed |
| US-10934303-B2 | Aryl ethene derivative and pharmaceutical composition containing same as active ingredient | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-03-02 | — | — | US | disclosed |
| US-20200078476-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2020-03-12 | — | — | US | disclosed |
| US-20190167820-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HWANG SUNG YEOUN (KR) | 2019-06-06 | — | — | US | disclosed |
| US-20190167820-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HWANG SUNG YEOUN (KR) | 2019-06-06 | — | — | US | disclosed |
| US-20190161490-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | NOVMETAPHARMA CO., LTD. (KR) | 2019-05-30 | — | — | US | disclosed |
| US-20190161490-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | NOVMETAPHARMA CO., LTD. (KR) | 2019-05-30 | — | — | US | disclosed |
| EP-3480186-A1 | NOVEL ARYL ETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | Kemimedi Co. Ltd (KR) | 2019-05-08 | — | — | EP | disclosed |
| EP-3480186-A1 | NOVEL ARYL ETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | Kemimedi Co. Ltd (KR) | 2019-05-08 | — | — | EP | disclosed |
| EP-3459936-A1 | NOVEL ARYL ETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | Kemimedi Co. Ltd (KR) | 2019-03-27 | — | — | EP | disclosed |
| EP-3459936-A1 | NOVEL ARYL ETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | Kemimedi Co. Ltd (KR) | 2019-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200078476-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ESRRG, ESR2, ESR1 | ESRRG 1/4885ESRRB 5/4885ESR1 3/4885 |
| US-20190167820-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ESRRG, ESR2, ESR1 | ESRRG 1/4885ESRRB 5/4885ESR1 3/4885 |
| US-11285226-B2 | Aryl ethene derivative and pharmaceutical composition containing same as active ingredient | ESRRG, ESR1, ESR2 | ESRRG 1/4885ESRRB 5/4885ESR1 2/4885 |
| US-20190161490-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ESRRG, ESR2, ESR1 | ESRRG 1/4885ESRRB 5/4885ESR1 3/4885 |
| US-10934303-B2 | Aryl ethene derivative and pharmaceutical composition containing same as active ingredient | ESRRG, ESR1, ESR2 | ESRRG 1/4885ESRRB 5/4885ESR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.